QPPV.COM KNOWLEDGE ASSESSMENT

Benefit-Risk Evaluation in Pharmacovigilance: Knowledge Assessment

Test your understanding of the concepts covered by Benefit-Risk Evaluation in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is benefit-risk evaluation considered a dynamic process rather than a one-time assessment?

Because the approved indication must be changed every year Because new information may alter understanding of benefits, risks or associated uncertainties throughout the product lifecycle Because only post-authorisation data are relevant to regulatory decisions Because the initial clinical trial results are automatically invalid after authorisation

Question 2 of 10 Which inspection finding most directly indicates a failure to link signal management with benefit-risk governance?

A signal assessment contains a literature reference The organisation cannot show who reviewed the signal, when the decision was made or how the outcome affected subsequent benefit-risk conclusions The product has more than one identified risk A PSUR includes both safety and efficacy information

Question 3 of 10 Why might a rare, severe adverse reaction have a greater effect on benefit-risk conclusions than a frequent, mild event?

Frequency is never relevant to risk assessment Severity and patient impact must be considered alongside frequency and other risk characteristics Rare events are presumed to be causally related Mild events are excluded from pharmacovigilance analyses

Question 4 of 10 An organisation uses MCDA to support a major benefit-risk decision. Which documentation would best support inspection readiness?

Only the final numerical score The criteria definitions, weighting rationale, evidence tables, scoring sheets, assumptions and sensitivity analyses A statement that the committee agreed with the score Only the names of the software used

Question 5 of 10 What is the primary contribution of an RMP to benefit-risk evaluation?

It establishes the commercial price of the medicine It describes how important risks will be monitored, characterised and minimised It replaces the need for PSUR benefit-risk conclusions It confirms that all potential risks have been eliminated

Question 6 of 10 A validated signal suggests a possible new cardiac risk, but the product provides substantial benefit for a serious disease. What is the most appropriate immediate interpretation?

The benefit-risk balance is automatically unfavourable The signal should be ignored until a causal relationship is proven beyond doubt The signal requires assessment in the context of the total safety profile, therapeutic benefits and clinical alternatives The signal can be addressed only by withdrawing the product

Question 7 of 10 Which example most appropriately illustrates how real-world evidence contributes to benefit-risk evaluation?

It replaces all randomised clinical trial evidence once a product is authorised It can refine understanding of effectiveness in broader or less selected patient populations It is relevant only for detecting manufacturing defects It should be used only when spontaneous reports are unavailable

Question 8 of 10 Which operational step should occur before selecting a benefit-risk method?

Issue a product information change regardless of the evaluation outcome Define the purpose, scope, populations, comparators, decision options and timeframe Obtain final sign-off from the QPPV before identifying the question Select the most complex available model

Question 9 of 10 What is a key limitation of relying on a numerical benefit-risk score without examining its assumptions?

Numerical methods cannot be used in regulatory settings A numerical output may create false precision and can be sensitive to input data, weights and modelling assumptions Quantitative methods cannot compare benefits and risks Sensitivity analysis makes model results less transparent

Question 10 of 10 A company concludes that targeted ECG screening is appropriate for patients at increased risk of QT-related arrhythmia. What additional activity best demonstrates that the risk-management strategy is functioning as intended?

Archive the recommendation without monitoring its use Track implementation and evaluate the effectiveness of the risk-minimisation measure Remove all discussion of QT prolongation from benefit-risk documentation Assume effectiveness because the measure was communicated to regulators

Benefit-Risk Evaluation in Pharmacovigilance: Knowledge Assessment

Cookie Settings